QCLS
What one share of Q/C Technologies holds
In Vitro and In Vivo Diagnostic Substances
Q/C Technologies’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$3.17 |
|---|---|
| Cash and investments | $1.34 |
| Book value | $1.96 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$25.61 | — | −$16.72 | — | — |
| 2022 | — | −$11.74 | — | −$9.48 | — | — |
| 2023 | — | −$5.33 | — | −$8.42 | — | — |
| 2024 | — | −$1,081 | — | −$357.21 | — | — |
| 2025 | — | −$8.66 | $1.01 | −$6.25 | — | $2.83 |